developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagssemaglutide

#semaglutide

All articles tagged with "semaglutide"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Archive
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

GLP-1 shows promise for patients with advanced fatty liver disease

Semaglutide shows antifibrotic signal in advanced MASH trial

Large Phase 2 trial data suggest semaglutide may reduce fibrosis in advanced MASH.
The benefit was reported without worsening liver inflammation.
Patients with compensated cirrhosis were included, addressing a major unmet-need group.
The semaglutide-zalfermin combination did not beat placebo.

DE

DT Editorial Team·Jul 17, 2026·via medicalxpress.com

More in Health→

$Semaglutide linked to lower bone fracture risk$

Semaglutide study links diabetes treatment to lower fracture risk

ENDO 2026 researchers reported a 15% lower fracture rate with semaglutide.
The study compared semaglutide with dulaglutide and two oral weight-loss therapies.
The analysis used U.S. electronic health records from 2016 through 2023.
Authors say prospective studies are still needed.

DE

DT Editorial Team·Jun 14, 2026·via medicalxpress.com

More in Health→

Injectable semaglutide shows early promise to improve fertility in women with PMOS

Injectable Semaglutide Shows Early Promise for Improving Fertility in Women with PMOS

Injectable semaglutide shows early promise for improving fertility in women with PMOS.
Study published in Fertility and Sterility from CU Anschutz.
Participants aged 12–35 who lost ≥10% body weight saw reproductive improvements.
Semaglutide may address both reproductive and metabolic symptoms of PMOS.

DE

DT Editorial Team·Jun 10, 2026·via medicalxpress.com

More in Health→

Scientists unlock a way to maintain GLP-1 efficacy long-term

NIH-backed research identifies a brain signaling pathway that could extend and strengthen semaglutide’s weight-loss эфф

Researchers linked semaglutide’s effect to cAMP signaling in area postrema neurons.
Some neurons sustain the response while others quickly lose it, which may help explain plateaus.
A PDE4 inhibitor, roflumilast, appeared to restore signaling in the mouse-model study.

DE

DT Editorial Team·May 28, 2026·via refractor.io

More in Innovation→

Ozempic Is Finally Turning the Tide Against Obesity, New Data Shows

GLP-1 prescribing surge coincides with a modest decline in obesity data

A large health-records dataset shows GLP-1 prescriptions rising more than fourfold since 2021.
The same dataset shows a modest decline in obesity rates over that span.
The data is early but suggests anti-obesity drugs may be shaping outcomes at scale.

DE

DT Editorial Team·May 26, 2026·via gizmodo.com

DE

DT Editorial Team·May 14, 2026·via medicalxpress.com

DE

DT Editorial Team·May 14, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 29, 2026·via livescience.com

DE

DT Editorial Team·Apr 19, 2026·via endpoints.news

DE

DT Editorial Team·Apr 2, 2026·via nature.com

DE

DT Editorial Team·Apr 1, 2026·via nature.com

More in Culture→

Popular weight loss and anti-inflammatory drugs may help prevent common heart rhythm disorder

Study maps how semaglutide and colchicine may help stop atrial fibrillation before it starts

Researchers studied how semaglutide and colchicine affect atrial remodeling after heart injury.
Semaglutide reduced fibrosis and helped preserve Connexin-43 placement between heart cells.
Colchicine blocked stress-signaling pathways including p38, JNK, and AKT.
Both drugs suppressed the NLRP3 inflammasome, a major inflammatory driver in heart disease progression.

More in Health→

Semaglutide study links diabetes drug to improved motivation in major depressive disorder

A study published in JAMA Psychiatry found semaglutide significantly improved measures of motivation in patients with major depressive disorder.
The reported effect focuses on motivation, a clinically important symptom domain in depression.
The supplied source does not provide trial size, effect size, or treatment protocol details, so the finding remains an early but notable signal.

More in Health→

A close up of an amber colored eye, with the face looking to the right of the image.

Wegovy Eye-Stroke Signal Draws Attention, but Experts Urge Caution

A new paper links Wegovy to a possible risk of ischemic optic neuropathy.
Experts say the evidence is preliminary and the reported rate remains very low.
Regulators are advising semaglutide users to seek urgent care for rapid vision changes.

More in Science→

Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests

Early Tirzepatide Analysis Raises New Questions About Lean Mass Loss in Obesity Treatment

A preliminary study suggests tirzepatide may cause greater lean body mass loss than semaglutide.
The same report says tirzepatide still helps patients lose more overall weight.
Because the study is awaiting peer review, the finding should be treated as provisional.
The result highlights growing clinical focus on body composition, not just total weight loss.

More in Health→

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial - Nature Medicine

Semaglutide analysis links liver-risk subgroup to reduced cardiovascular events

SELECT subgroup analysis focused on patients at elevated fibrosis risk.
Semaglutide reduced major adverse cardiovascular events across reported fibrosis-risk definitions.
Fatty liver index fell more with semaglutide than with placebo over 104 weeks.

More in Health→

GLP-1 receptor agonist fails to halt Alzheimer’s disease

Semaglutide Misses in Phase 3 Alzheimer’s Trials, Narrowing a Hoped-For New Path

Phase 3 EVOKE(+) trials found semaglutide did not slow clinical progression of Alzheimer’s disease.
Earlier preclinical, observational, and small trial signals had raised hopes for GLP-1 drugs in neurodegeneration.
The negative result still helps refine future Alzheimer’s research around inflammation, vascular dysfunction, and metabolic pathways.

More in Health→